

# Curriculum Vitae

## Huldrych F. Günthard



### BUSINESS INFORMATION

---

<b>business address</b>	University Hospital Zurich Department of Infectious Diseases and Hospital Epidemiology Rämistrasse 100, 8091 Zurich, Switzerland
<b>phone</b>	+41 44 255 34 50
<b>e-mail</b>	huldrych.guenthard@usz.ch

### EDUCATION

---

<b>1984 - 1990</b>	Medical School, University of Zurich, Zurich (UZH)
<b>1993</b>	Doctoral Thesis Medical Faculty, UZH, ECFMG Certificate
<b>1996</b>	Swiss Board of Internal Medicine (FMH Innere Medizin)
<b>1999</b>	Swiss Board of Infectious Diseases (FMH für Infektiologie)
<b>2006</b>	'Venia Legendi' in Infectious Diseases, UZH, Faculty of Medicine 'Titularprofessor' University of Zurich, Faculty of Medicine
<b>2009</b>	'Ausserordentlicher Professor a.p. für klinische Infektiologie', UZH, Faculty of Medicine
<b>2010</b>	'Promotionsrecht' at der Mathematisch Naturwissenschaftlichen Fakultät UZH (affiliation to and authorization by the faculty of science of the University of Zurich to educate PhD students)
<b>2016</b>	„Ordentlicher Professor für klinische Infektiologie, a.p.“ (Full Professor) UZH, Faculty of Medicine

### POSTGRADUATE EDUCATION

---

<b>1991 - 1993</b>	University Hospital of Zurich, Division of infectious Diseases, Zurich
<b>1991</b>	Scientific resident, USZ
<b>1992</b>	Resident HIV-outpatient clinic, USZ
<b>1993</b>	Resident Infectious Disease consultation service, USZ
<b>1994 - 1/1996</b>	Resident Internal Medicine, Stadtspital Triemli, Zurich
<b>2/1996 - 2/1999</b>	Postdoctoral research / Infectious Disease fellowship, UCSD San Diego
<b>5/1999 - 10/2003</b>	Staff physician (Oberarzt) USZ, Div. Inf. Dis. and Hosp. Epid.
<b>5/1999 - present</b>	Head HIV-research laboratory Division of Infectious Diseases
<b>11/2003 - 08/2005</b>	Acting senior staff physician (Leitender Arzt a.i.)
<b>09/2005 - present</b>	Senior staff physician (Leitender Arzt)
<b>2013 - present</b>	Deputy director of the Dept. Inf. Dis. and Hosp. Epid., USZ

### Selected teaching activities

---

Medical students at different levels: lectures, "Mantelstudium: Forschung in der Medizin, Labormedizin, , lectures at MNF (Institute of Medical Virology, Molekulare Medizin), Studentenkurse (e.g. Differentialdiagnose Innere Medizin).

### Supervisory experience (research)

---

**PhD students:** V. von Wyl, A. Scherrer, Ph. Rieder, C. Althaus, F. di Giallonardo, V. Vongrad, W.L. Yang, C. Oberle, V. Strouvelle, T. Turk, S. Chaudron, A. Rindler, L. Jörimann (finished), J. Tschumi, J. Ramirez Duran (ongoing)  
**MD laboratory/Epidemiology thesis:** P. Kaiser, A. Schmid, A. Pyngottu (finished), Caroline Lanz, Marc Weber (ongoing)  
**Post Docs:** V. von Wyl, S. Gianella, A. Scherrer, D. Braun, R. Kouyos, V. Vongrad, Y. Lim, C. Kadelka, I. Abela  
**PD:** R. Kouyos, D. Braun, A. Scherrer, K. Kusejko,  
**Academic Positions:** V. von Wyl, Prof. UZH, R. Kouyos, Prof. UZH, S. Gianella, Professor, UCSD, USA, K. Kusejko, SNF Starting grant, UZH (Förderungsprofessur)

## Key funding sources:

SNF, Systems X, Swiss HIV Cohort Study, CRPP viral infectious diseases, Zurich PHI Study, NIH, Unrestricted research Grant from Gilead, Yvonne Jacob Foundation

## Selected professional activities

Member research council of Swiss National Research Foundation, Division Biology and Medicine (2010-2018)  
President and PI of the Swiss HIV Cohort Study (since 2012)  
Program committee member: Conference on retroviruses and opportunistic infections (CROI) (since 2014), Co-Chair Track A, AIDS-2018, IAS, Amsterdam, Co-Chair basic science, EACS, 2019, Basel Switzerland  
Member International Antiviral Society–USA, Antiretroviral Guidelines Panel, since 2010 (Chair 2013-2016), IAS-USA HIV Drug resistance mutations group, since 2006, IAS-USA HIV-Resistance testing guidelines panel (Since 2007, chair since 2018). Member of the Swiss Academy of Medical Sciences (Einzelmitglied), (since 2018), Swissmedic: Extraordinary Member of the Human Medicines Expert Committee (2021-2024)


## Key publications last 5 years (full publication list see web of science: F-1724-2011)

1. Kouyos RD, Rusert P, Kadelka C, Huber M, Marzel A, Ebner H, Schanz M, Liechti T, N. F, Braun DL, Scherrer A, Weber J, Uhr T, Baumann NS, Leemann C, Kuster H, Chave J-P, Cavassini M, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Böni J, Metzner KJ, **Günthard HF\***, Trkola A\*, and the SHCS (2018). *Tracing HIV-1 strains that imprint broadly neutralising antibody responses*. *Nature*. 2018;561(7723):406-410; [\*shared last author] [www.ncbi.nlm.nih.gov/pubmed/30202088](http://www.ncbi.nlm.nih.gov/pubmed/30202088)
2. **Günthard HF**, Calvez V, Paredes R, Pillay D, Shafer RW, Wensing AM, Jacobsen DM, Richman DD. **Resistance Testing for Integrase Strand Transfer Inhibitors in Naive, Human Immunodeficiency Virus-infected Individuals Reply**. *Clinical Infectious Diseases*. 2019; 68(11),1977–1978. doi: 10.1093/cid/ciy1022 <https://doi.org/10.1093/cid/ciy1022> .
3. Bachmann N, von Siebenthal C, Vongrad V, Turk T, Neumann K, Beerenwinkel N, Bogojeska J, Fellay J, Roth V, Lim Kok Y, Thorball CW, Borghesi A, Parbhoo S, Wieser M, Böni J, Perreau M, Klimkait T, Yerly S, Battegay M, Rauch A, Hoffmann M, Bernasconi E, Cavassini M, Kouyos RD\*, **Günthard HF\***, Metzner KJ\*, and SHCS. *Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART*. *Nature Communications*. 2019;10(1):3193. doi: 10.1038/s41467-019-10884-9 [\*shared last author] [www.ncbi.nlm.nih.gov/pubmed/30601950](http://www.ncbi.nlm.nih.gov/pubmed/30601950)
4. Abela IA, Scherrer AU, Böni J, Yerly S, Klimkait T, Perreau M, Hirsch HH, Furrer H, Calmy A, Schmid P, Cavassini M, Bernasconi E, **Günthard HF**, and SHCS. **Emergence of drug resistance in the Swiss HIV Cohort Study under potent antiretroviral therapy is observed in socially disadvantaged patients**. *Clinical Infectious Disease*. 2020;70(2):297-303. doi: 10.1093/cid/ciz178 [www.ncbi.nlm.nih.gov/pubmed/30843028](http://www.ncbi.nlm.nih.gov/pubmed/30843028)
5. Wan C\*, Bachmann N\*, Mitov V, Blanquart F, Céspedes S, Turk T, Neumann K, Beerenwinkel N, Bogojeska J, Fellay J, Roth V, Böni J, Perreau M, Klimkait T, Yerly S, Battegay M, Walti L, Calmy A, Vernazza P, Bernasconi E, Cavassini M, Metzner KJ\*\*, **Günthard HF\*\***, Kouyos RD\*\*, and the SHCS. **Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART**. *Nature Communications*. 2020;11(1):5542. doi: 10.1038/s41467-020-19198-7. \*, \*\*: *contributed equally* <https://pubmed.ncbi.nlm.nih.gov/33139735>
6. Pyngoitu A\*, Scherrer AU\*, Kouyos R, Huber M, Hirsch H, Perreau M, Yerly S, Calmy A, Cavassini M, Stöckle M, Furrer H, Vernazza P, Bernasconi E, **Günthard HF**, and the SHCS. **Predictors of virological failure and time to viral suppression of first line integrase inhibitor based antiretroviral treatment**. *Clinical Infectious Diseases*, 2021;73(7):e2134-e2141. doi: 10.1093/cid/ciaa1614., \**contributed equally* <https://pubmed.ncbi.nlm.nih.gov/33095848>
7. ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group. **Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial**. *Lancet Infectious Diseases*. 2022;22(5):622-635 <https://pubmed.ncbi.nlm.nih.gov/35939810>
8. Chaudron SE, Leemann C, Kusejko K, Nguyen H, Tschumi N, Marzel A, Huber M, Böni J, Perreau M, Klimkait T, Yerly S, Ramette A, Hirsch HH, Rauch A, Calmy A, Vernazza P, Bernasconi E, Cavassini M, Metzner KJ, Kouyos RD, **Günthard HF**, and the SHCS. **A systematic molecular epidemiology screen reveals numerous HIV-1 superinfections in the Swiss HIV Cohort Study**. *Journal of Infectious Diseases* 2022; 226(7):1256-1266. doi: 10.1093/infdis/jjac166 <https://pubmed.ncbi.nlm.nih.gov/35485458>
9. Gandhi RT, Bedimo R, Hoy JF, Landovitz RJ, Smith DM, Eaton EF, Lehmann C, Springer SA, Sax PE, Thompson MA, Benson CA, Buchbinder SP, Del Rio C, Eron Jr JJ, **Günthard HF**, Molina JM, Jacobsen DM, Saag MS. **Antiretroviral drugs**

for treatment and prevention of HIV infection in adults: 2022 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2022; doi: 10.1001/jama.2022.22246

<https://pubmed.ncbi.nlm.nih.gov/36454551>

10. West E, Zeeb M, Grube C, Kuster H, Wanner K, Scheier T, Neumann K, Jörimann L, Hampel B, Metzner KJ, Kouyos RD, Braun DL, Günthard HF. Sustained viral suppression with dolutegravir monotherapy over 192 weeks in patients starting combination antiretroviral therapy during primary HIV infection (EARLY-SIMPLIFIED): a randomized, controlled, multi-site, non-inferiority trial. Clinical Infectious Diseases. 2023;ciad366. doi: 10.1093/cid/ciad366  
<https://pubmed.ncbi.nlm.nih.gov/37338148>



Zürich, 13<sup>th</sup> December 2023,

H. Günthard